Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

AL-108 cleared for clinical study in schizophrenia-related cognitive impairment

March 30, 2007

AZ-001 meets two-hour pain-relief endpoint in migraine

March 30, 2007

Botox to be studied for paroxysmal trigeminal neuralgia pain

March 29, 2007

SSA-426: a novel antidepressant with dual activity on the 5-HT transporter and the 5-HT1A receptor

March 29, 2007

Snapshots on new candidates to reduce Abeta pathology in AD

March 29, 2007

AZ-004 reduces agitation in schizophrenic patients

March 28, 2007

Modiodal launched in Japan

March 28, 2007

Cephalon files for European approval of fentanyl effervescent buccal tablet

March 28, 2007

Phase III study of vilazodone in depression completes enrollment

March 28, 2007

New agents for treating neurological disorders disclosed in recent patents

March 28, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...